Publications by authors named "Zallot C"
Article Synopsis
- The study aimed to find the best treatment strategies for perianal Crohn's disease (PCD) by evaluating medical and surgical options over a 20-year period.
- Researchers reviewed the medical records of 200 patients and found that combining TNFα antagonists with immunosuppressants and performing certain surgeries improved the chances of fistula closure.
- They concluded that a combined approach, specifically using medical therapy alongside seton placement and additional surgery within one year, is the most effective management for PCD patients.
Introduction: The objective of this study was to describe the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after stopping for loss of response or intolerance.
Methods: We conducted a prospective multicenter observational cohort study including adult patients with clinically (CD Activity Index >150) and objectively active luminal CD in whom IFX was reintroduced after at least 6 months of discontinuation. The reasons for the initial discontinuation could be a secondary loss of response or IFX intolerance.
Article Synopsis
- Budesonide is the main treatment for microscopic colitis (MC), but frequent relapses and some patients being intolerant lead to the exploration of anti-TNF therapy in those who do not respond to budesonide.
- In a study of 14 budesonide-refractory MC patients treated with anti-TNF agents, 35.7% achieved clinical remission and 64.3% showed improvement in stool frequency after 12 weeks.
- The study concludes that anti-TNF therapy can be effective for about half of patients with MC who fail budesonide, marking a significant finding in the treatment of this condition.
Article Synopsis
- Crohn's disease (CD) affects around 20% of patients with complications such as perianal fistulas, where achieving permanent closure remains difficult for doctors.
- This study aimed to explore how serum adalimumab (ADA) levels relate to the clinical remission of fistulas associated with CD.
- Results showed that higher serum ADA concentrations were linked to successful clinical remission, with 44% of patients achieving it, but no significant difference was found in ADA levels between those with and without healed fistulas.
Background: Telemedicine has shown promising results in the follow up of patients with inflammatory bowel disease. This study compared quality of life and disease activity in patients with inflammatory bowel disease monitored using a telemedicine platform versus standard care.
Methods: In this prospective multicenter study, patients with active inflammatory bowel disease were randomized to EasyMICI-MaMICI telemedicine platform or standard care.
In March 2020, the COVID-19 pandemic disrupted most of the routine outpatient activities in Italian hospitals and Prevention Departments, including those vaccinations which were not urgent and/or scheduled for children aged 0-6 years. Since June 2020, when the pandemic entered a milder phase, in the alpine Province of Belluno (Veneto, North-Eastern Italy), 12,152 doses of vaccine against tick-borne encephalitis have been administered by means of the innovative "drive-through" modality. No significant adverse events have occurred and popular demand has steadily grown, proving the "drive-through" approach to be safe, efficient and successful.
View Article and Find Full Text PDFTechnological progress, including virtual clinics, web or smartphone-based applications, and assessment of fecal calprotectin (FC) at home has favored the implementation of treat to target strategies for patients with inflammatory bowel diseases (IBD). Although these innovations are promising and have been associated with a significant reduction in health costs, their application in clinical practice is limited. Here, we summarize the most recent literature on virtual clinics and available FC home tests.
View Article and Find Full Text PDFBackground And Aims: In rare cases, the diagnosis of Crohn's disease (CD) can only be achieved using small bowel capsule endoscopy (SBCE). We investigate the characteristics of patients with CD only visible on SBCE and assess their disease course.
Methods: Data of all adult patients with confirmed CD diagnosis based on SBCE with normal endoscopic and cross-sectional imaging findings were retrospectively collected in three tertiary-level hospitals from January 2014 to March 2020.
The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection.
View Article and Find Full Text PDFBackground: The management of Crohn's disease patients with perianal lesions and anti-TNF failure is challenging.
Aims: To assess the effectiveness of vedolizumab in perianal Crohn's disease and the predictors of success in a real-life cohort.
Methods: We conducted a nationwide multicentre cohort study in patients with perianal Crohn's disease who received vedolizumab.
Background: To lighten the burden on health-care spending, switching from the infliximab originator to a biosimilar in patients with inflammatory bowel disease (IBD) is advocated. However, the uptake of biosimilars lacks initiatives aimed at educating patients.
Aims: To explore the impact of a gastroenterologist's interview on IBD patients' acceptance for switching from infliximab bio-originator Remicade® to its biosimilar CT-P13 Inflectra®.
Background: Standard high-volume polyethylene glycol [PEG] bowel preparations [PEG-4L] are recommended for patients with inflammatory bowel disease [IBD] undergoing colonoscopy. However, low-volume preparations [≤2 L of active volume] are often used in clinical practice. The aim of this study was to evaluate the efficacy, tolerability, and safety of the various bowel preparations for patients with IBD, including low-volume preparations.
View Article and Find Full Text PDFBackground And Aims: Histological healing may be the ultimate therapeutic goal in ulcerative colitis [UC]. We investigated, for the first time, the association between vedolizumab trough levels and histological healing in UC.
Methods: This is a single-centre retrospective cohort study including all consecutive UC patients on vedolizumab maintenance therapy who had a histological evaluation blindly to clinical data and underwent therapeutic drug monitoring, between June 2014 and March 2018.
Background: Data about the outcomes after adalimumab dose de-escalation in inflammatory bowel disease (IBD) are scarce.
Objectives: To assess the outcomes after adalimumab dose de-escalation, and to identify potential factors associated with failure.
Methods: Retrospective, observational study including all IBD patients who had undergone adalimumab dose de-escalation to 40 mg every three weeks across seven GETAID centers, between June 2011 and September 2017.
Background: The correlation between vedolizumab trough levels during induction therapy and mucosal healing remains unknown.
Aim: To compare early vedolizumab trough levels in patients with and without mucosal healing within the first year after treatment initiation.
Methods: We prospectively collected vedolizumab trough levels in all inflammatory bowel disease patients at weeks 2, 6 and 14 of vedolizumab treatment in three French referral centres between 1 June 2014 and 31 March 2017.
Background: Improvement of quality of life is a main objective in inflammatory bowel disease [IBD] management. Data on sexual dysfunction [SD] in IBD are scarce. This study compared rates of SD between IBD patients and healthy controls [HC], and searched for predictors of SD.
View Article and Find Full Text PDFBackground And Aims: Using sigmoidoscopy as the gold standard, we assessed the accuracy, and the responsiveness to change, of diffusion-weighted magnetic resonance colonography in ulcerative colitis, using the Nancy score.
Methods: A total of 29 ulcerative colitis patients, having undergone at least two diffusion-weighted magnetic resonance colonographies, were included. Disease activity was evaluated using the Mayo endoscopic subscore and the Nancy score.
Background And Aims: Bowel damage in Crohn's disease [CD] is defined as the presence of intestinal strictures, fistulas or abscesses. Early disease may represent a window of opportunity for timely intervention. We evaluated disease activity and severity by the Lémann Index [LI] and the Magnetic Resonance Index of Activity [MaRIA] score, and their prognostic value in early CD.
View Article and Find Full Text PDFBackground: Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity.
Methods: We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions for cancer treatment.
Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
Eur J Gastroenterol Hepatol
August 2015
Background And Aims: The vaccination rate against hepatitis B virus (HBV) is low in inflammatory bowel disease (IBD) patients. The Consensus from the European Crohn's and Colitis Organisation on opportunistic infections recommends testing all IBD patients for HBV at diagnosis and vaccinating all HBV-negative patients. We compared the efficacy of HBV vaccine between IBD patients and healthy controls and investigated the impact of immunosuppressive therapy on vaccine response in IBD patients.
View Article and Find Full Text PDFSelf-insertion of a nasogastric tube for home enteral nutrition: a pilot study.
JPEN J Parenter Enteral Nutr
September 2014
Background: Enteral tube feeding can be a source of discomfort and reluctance from patients. We evaluated for the first time the tolerability of self-insertion of a nasogastric (NG) tube for home enteral nutrition (EN).
Materials And Methods: All patients requiring enteral tube feeding for chronic diseases were enrolled in a therapeutic patient education (TPE) program at Nancy University Hospital.